AACR 2023 | Will atezolizumab and bevacizumab be the new SOC in high-risk HCC?

Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD , National Cancer Centre Singapore & Duke-NUS Medical School Singapore, Singapore, comments on the future of adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma (HCC), which was assessed in Phase III IMbrave050 trial (NCT04102098). As recurrence was reduced, this combination therapy has potential to be the new standard of care, especially as there are no previous efficacious therapies available in this group of patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.